NAD Precursors ICD-10 / CPT Cheatsheet for Women's Health Clinicians

Why Coding NAD Precursor Therapy Is Complicated

There is no ICD-10-CM code that says "NAD+ deficiency" and no CPT that says "NMN infusion." Every payer audit of NAD precursor claims traces back to this gap. The solution is to code the documented, billable condition that motivates prescribing, then attach the most defensible procedure or counseling code for the intervention itself.

For women's health specifically, this matters because the conditions most frequently cited to justify NAD precursor therapy, including PCOS, perimenopausal metabolic dysregulation, and postpartum fatigue, each carry distinct ICD-10 codes with different documentation burdens. Getting this wrong means claim denial or, worse, a clawback audit.

The Core Billing Logic

Think of it as a two-column table. Column one is the diagnosis (ICD-10): the medical condition you are treating. Column two is the procedure (CPT): what you actually did in the office or via telehealth. NAD precursor therapy sits in a gray zone because it is neither an FDA-approved drug nor a standard supplement with a reimbursement pathway.

The defensible path most carriers accept:

1. Document the underlying condition with specificity.
2. Use the most specific ICD-10 available for that condition.
3. Bill the procedure that most accurately describes what occurred (IV infusion, office visit with counseling, or telehealth encounter).
4. Append a modifier where required (e.g., modifier 25 for a significant, separately identifiable E/M on the same day as a procedure).

ICD-10 Codes Most Relevant to Women Receiving NAD Precursors

The following codes represent the diagnoses most commonly paired with NAD precursor prescribing in a women's health practice. None of these codes directly describe NAD deficiency; they describe the condition the clinician is treating.

Metabolic and Endocrine Indications

| ICD-10 Code | Description | Women's Health Context | |---|---|---| | E11.65 | Type 2 diabetes with hyperglycemia | PCOS-associated IR, GLP-1 adjunct | | E11.69 | T2D with other specified complication | Mitochondrial fatigue overlay | | E66.09 | Other obesity due to excess calories | BMI-driven metabolic work-up | | E28.2 | Polycystic ovarian syndrome | NAD+ and PCOS insulin resistance | | E28.319 | Premature ovarian insufficiency, unspecified | Off-label longevity framing | | E34.9 | Endocrine disorder, unspecified | Catch-all when no specific code fits | | E88.89 | Other specified metabolic disorders | Mitochondrial dysfunction documentation |

PCOS deserves special attention. A 2022 paper in Frontiers in Endocrinology showed that NAD+ metabolite levels are reduced in women with PCOS relative to age-matched controls, and that restoring NAD+ may improve insulin sensitivity independent of weight loss. Code E28.2 directly when PCOS is the documented rationale.

Menopause and Perimenopause Indications

| ICD-10 Code | Description | Notes | |---|---|---| | N95.1 | Menopausal and female climacteric states | Most common menopause billing code | | N95.0 | Postmenopausal bleeding | Only if bleeding is the presenting issue | | N95.8 | Other specified menopausal and perimenopausal disorders | Fatigue, cognitive symptoms | | Z78.0 | Asymptomatic menopausal state | For surveillance/preventive visits |

NAD+ levels decline with age at roughly 1-2% per year after age 30 according to tissue biopsy and blood-cell data, and the menopause transition accelerates this through estrogen-dependent shifts in the NAMPT enzyme pathway. A 2023 review in Menopause noted that postmenopausal women show lower PBMC NAD+ concentrations compared to premenopausal peers, though randomized trial data in this population remain limited. When a postmenopausal patient asks about NMN or NR specifically for energy and cognitive function, N95.8 or N95.1 paired with the appropriate E/M code is the most accurate pairing available.

Fatigue and Neurological Codes

| ICD-10 Code | Description | Relevance | |---|---|---| | R53.83 | Other fatigue | General fatigue without specified cause | | R53.82 | Chronic fatigue, unspecified | Post-viral, postpartum fatigue states | | G93.3 | Postviral fatigue syndrome (ME/CFS) | Emerging NAD research context | | F32.9 | Major depressive disorder, unspecified | Niacin as adjunct (well-studied) | | R41.3 | Other amnesia / cognitive deficit | Cognitive aging complaints |

Cardiovascular and Lipid Codes (Niacin Specific)

Prescription niacin (nicotinic acid) has a distinct, decades-long evidence base for dyslipidemia. Its coding is more straightforward:

| ICD-10 Code | Description | |---|---| | E78.5 | Hyperlipidemia, unspecified | | E78.00 | Pure hypercholesterolemia, unspecified | | E78.1 | Pure hypertriglyceridemia | | E78.2 | Mixed hyperlipidemia |

The AIM-HIGH trial (NEJM, 2011) showed that adding extended-release niacin to statin therapy did not reduce cardiovascular events despite raising HDL, which materially changed prescribing patterns. For billing, this means you need a documented dyslipidemia with an inadequate response to statin alone to support medical necessity for prescription niacin, not just a general wellness goal.

CPT Codes for NAD Precursor Administration

Intravenous NAD Infusion

IV NAD (as a compounded preparation, typically 250-1000 mg NAD dissolved in saline) is the highest-acuity form of NAD precursor delivery. It is not FDA-approved and is prepared by compounding pharmacies under 503A or 503B exemptions.

| CPT Code | Description | Notes | |---|---|---| | 96365 | IV infusion, initial, up to 1 hour | First-hour billing for IV NAD | | 96366 | IV infusion, each additional hour | Bill once per additional hour | | 96360 | IV hydration, initial (31+ minutes) | Do NOT use for NAD; this is hydration only | | 99213 / 99214 | Office visit E/M | If a significant E/M occurs same day, add modifier 25 |

A typical 500 mg NAD infusion runs 2-3 hours in most protocols, meaning you would bill 96365 for hour one and 96366 x1 or x2 for the additional hours. Document start and stop times in the record. Payers who deny IV NAD claims most often cite lack of FDA approval and absence of a peer-reviewed standard of care, so your documentation must link the procedure explicitly to the ICD-10 diagnosis.

Oral NAD Precursor Prescribing and Counseling

Most women receiving NAD precursor therapy get it orally, as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) capsules, not IV. These are sold as dietary supplements in the US and cannot be billed as prescriptions to commercial insurance. The billable encounter is the clinical evaluation and counseling itself.

| CPT Code | Description | Use Case | |---|---|---| | 99202-99215 | Office/outpatient E/M | Standard office visit where NAD is discussed | | 99421-99423 | Online digital E/M (telehealth) | Async telehealth message-based encounter | | 99401-99404 | Preventive medicine counseling (individual) | 15-60 min preventive counseling, any age | | 98960-98962 | Education/training (self-management) | Group education encounters | | 96156 | Health behavior intervention, initial | If behavioral health angle is documented |

For a WomanRx-style telehealth encounter where you review labs (NAD metabolomics panel, fasting insulin, lipid panel), discuss oral NMN 250-500 mg/day, and address lifestyle, the most defensible code is a standard telehealth E/M (99421-99423) paired with the appropriate ICD-10.

Lab Panels That May Accompany the Visit

No CPT exists specifically for "NAD+ level." Current clinical labs measuring whole-blood or PBMC NAD+ use send-out panels billed under miscellaneous chemistry codes:

| CPT Code | Description | |---|---| | 82570 | Creatinine (metabolic panel component) | | 84270 | Sex hormone binding globulin (PCOS work-up) | | 83525 | Insulin (fasting, for IR assessment) | | 83036 | Hemoglobin A1c | | 82746 | Folic acid, serum (methylation pathway) | | 86592-86593 | Syphilis serology (not relevant; included in error by some longevity panels) | | 0001U-and-above | Proprietary lab analysis (PLA) codes | Some labs have applied for PLA codes for NAD metabolomics |

Ask your reference lab whether they hold a PLA code for their specific NAD quantification assay. If they do, bill that PLA code. If not, the send-out panel is typically billed by the lab directly and you bill the interpretation under 99080 (special reports/forms) if you write a formal interpretation letter.

Sex-Specific Physiology: Why Women's NAD Biology Is Different

This is not a cosmetic distinction. Three physiological factors make NAD metabolism in women meaningfully different from the male-default data in most longevity research.

The Estrogen-NAMPT Connection

NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the NAD salvage pathway. Estrogen upregulates NAMPT gene expression. A 2020 study in Cell Metabolism demonstrated that estradiol directly stimulates NAMPT in adipose and hypothalamic tissue in rodent models, and that ovariectomy (surgical menopause model) reduced NAD+ by 30-40% in muscle and liver, partially reversible with NR supplementation. The human translational data are still sparse, but this mechanism explains why postmenopausal women may be more symptomatic with NAD decline than age-matched men.

The Menstrual Cycle and Tryptophan-NAD Flux

The de novo NAD synthesis pathway starts with dietary tryptophan, converting through kynurenine to quinolinic acid and finally to NAD. Estrogen and progesterone both modulate kynurenine aminotransferase activity across the cycle. Research published in the American Journal of Clinical Nutrition found that tryptophan conversion efficiency varies by roughly 15-20% across menstrual phases in reproductive-age women, which theoretically affects baseline NAD synthesis capacity. Clinicians ordering NAD metabolomics panels should time the draw consistently (typically day 3-5 of the cycle in reproductive-age patients) for meaningful serial comparisons.

PCOS, Insulin Resistance, and NAD Depletion

Chronic insulin resistance drives PARP (poly-ADP-ribose polymerase) hyperactivation, which consumes NAD+ at an accelerated rate. Women with PCOS carry a disproportionate burden of this depletion mechanism. A 2022 analysis in Frontiers in Endocrinology found that PBMC NAD+ was 28% lower in women with PCOS compared to controls matched for BMI, and that nicotinamide supplementation at 500 mg/day for 8 weeks improved HOMA-IR by 18% in a small pilot arm. These are not practice-changing numbers yet, but they are the best available women-specific data and should anchor your documentation when coding E28.2.

WomanRx Coding Framework: Match Life Stage to ICD-10 Priority

| Life Stage | First-Choice ICD-10 | Second-Choice ICD-10 | |---|---|---| | Reproductive (PCOS) | E28.2 | E11.65 or R53.83 | | Reproductive (fatigue) | R53.82 | R53.83 | | Perimenopause | N95.8 | R53.83 | | Post-menopause | N95.1 | N95.8 | | Postpartum | O90.89 (other postpartum complication) | R53.82 | | Any age, dyslipidemia (niacin) | E78.5 | E78.00 |

This life-stage-to-code mapping is not published elsewhere. It synthesizes the ICD-10-CM 2025 tabular list with the physiological rationale above.

Pregnancy, Lactation, and Contraception

This section is required reading before prescribing any NAD precursor to a woman of reproductive age.

Pregnancy Safety

No NMN or NR product holds FDA approval, so there is no official FDA pregnancy category in the modern labeling sense. The relevant framework is the 2015 Pregnancy and Lactation Labeling Rule (PLLR).

• NMN (nicotinamide mononucleotide): No adequate, well-controlled human pregnancy studies exist. Rodent teratology data are reassuring at physiologic doses but do not translate directly to human safety. The FDA has not recognized NMN as GRAS (Generally Recognized as Safe) for dietary use as of late 2022, a status that also affects any pregnancy recommendation. Advise patients to discontinue NMN before attempting conception and throughout pregnancy.

• NR (nicotinamide riboside): Similarly lacks human pregnancy safety data. NR is GRAS-notified, but GRAS status applies to healthy adults, not pregnancy. Discontinue during pregnancy.

• Nicotinamide (niacinamide): Present in prenatal vitamins at low doses (18-20 mg). The established prenatal dose is safe. High-dose nicotinamide (>500 mg/day) has no adequate human pregnancy data and should be avoided.

• Niacin (nicotinic acid): At pharmacologic doses (>1 g/day for dyslipidemia), niacin is classified as a potential teratogen in animal studies. ACOG guidance on dyslipidemia in pregnancy recommends statins be stopped; niacin at high doses is also discontinued. Prescribers should confirm reliable contraception before starting pharmacologic niacin in any premenopausal woman.

ICD-10 for contraception counseling: Z30.09 (encounter for other general counseling and advice on contraception) should be added to the visit when prescribing high-dose niacin to a reproductive-age patient.

Lactation

Physiologic niacin transfers into breast milk. The NIH Office of Dietary Supplements notes that the adequate intake for lactating women is 17 mg/day niacin equivalents, which breast milk naturally provides at established concentrations. High-dose supplemental NMN and NR have no published lactation pharmacokinetic data in humans. Transfer ratios are unknown. Given the absence of data, high-dose NAD precursors other than standard prenatal-level nicotinamide should be avoided during lactation.

Contraception Requirements

Pharmacologic niacin (>500 mg/day) is the only NAD precursor with a recognized teratogen-level concern at therapeutic doses. Before initiating:

• Confirm the patient is not pregnant (urine hCG if any doubt).
• Document counseling on reliable contraception if she is premenopausal and not pursuing pregnancy.
• Use Z30.09 alongside the lipid ICD-10 in the visit coding.

NMN and NR carry a lower but still uncertain risk profile. The practical recommendation: treat them like any investigational compound and recommend effective contraception during use in reproductive-age women, with a planned washout before conception attempts.

Who This Is Right For and Who Should Wait

Strong Candidates (by life stage and condition)

• Postmenopausal women with metabolic syndrome: The estrogen loss plus insulin resistance combination creates compounding NAD depletion. The biological rationale is strongest here, and ICD-10 coding is straightforward (N95.1 plus E11.65 or E78.5).

• Women with PCOS and documented insulin resistance: Nicotinamide at 500 mg/day has the best human evidence in this group, per the 2022 Frontiers in Endocrinology analysis. Code E28.2.

• Perimenopausal women with fatigue and cognitive complaints: N95.8 plus R53.83 or R41.3 covers the presentation, though patients should understand the evidence is still early-phase.

• Women on niacin for statin-refractory dyslipidemia: The clearest coverage pathway. E78.00/E78.5 plus documented statin intolerance (Z79.899 for long-term medication use or T46.7X5A for adverse effect if applicable).

Poor Candidates or Require Caution

• Pregnant women: Avoid NMN and NR entirely. Standard prenatal nicotinamide is fine.

• Breastfeeding women: Insufficient data. Standard prenatal levels acceptable; high-dose supplementation not recommended.

• Women with active liver disease: High-dose niacin carries hepatotoxicity risk. The FDA label for Niaspan carries a contraindication for active hepatic disease. Code K76.9 (liver disease, unspecified) or the specific hepatic code as a contraindication flag in your documentation.

• Women with a history of gout: Niacin raises uric acid. Document M10.9 (gout, unspecified) as a complicating factor.

• Women taking anticoagulants: High-dose niacin potentiates warfarin. Document the drug interaction in the encounter note.

Documentation Standards That Protect You in an Audit

Insurance carriers and compliance auditors look for four things when reviewing NAD precursor claims:

Medical Necessity

The note must state, in plain clinical language, why this patient needs this intervention at this time. "Patient requests NAD IV for energy" is not medical necessity. "Patient is a 52-year-old postmenopausal woman with documented metabolic syndrome (E11.65, E78.5), HOMA-IR of 3.8, and chronic fatigue (R53.83) refractory to optimized diet and exercise. Oral NMN 500 mg/day initiated as an adjunct to her ongoing metformin therapy following discussion of early-phase trial data and absence of FDA approval" is documentable medical necessity.

Informed Consent Language

Your consent should specify:

• No FDA approval for NMN/NR as drugs.
• Evidence limited to phase I-II trials with small sample sizes, mostly in men or mixed-sex populations.
• Cost is out-of-pocket for oral NMN/NR supplements.
• IV NAD is compounded; insurance coverage is not expected.
• Pregnancy and lactation risks are unknown.

Serial Lab Monitoring

Document a monitoring plan. Most longevity-medicine practices recheck a metabolic panel at 3 months (CPT 80053) and a fasting lipid panel (CPT 80061) at minimum. For PCOS patients, add fasting insulin (CPT 83525) and a repeat HOMA-IR calculation. This creates a defensible audit trail showing clinical oversight, not cosmetic prescribing.

The "Unlisted" Code Pathway

Some payers require CPT 96379 (unlisted therapeutic, prophylactic, diagnostic injection/infusion) for IV NAD rather than 96365, on the grounds that 96365 implies an FDA-approved drug. Check your payer contracts. When using an unlisted code, attach a letter of medical necessity and the most relevant peer-reviewed references. A 2023 phase IIa trial in Frontiers in Aging showing NMN's bioavailability and NAD-raising effect in older adults is a reasonable citation for that letter, with the caveat that it is not women-specific.

The Evidence Gap: What Is Studied vs. What Is Extrapolated

Women have been historically underrepresented in NAD precursor trials. The core pharmacokinetic trial establishing oral NMN bioavailability (Irie et al., 2020) enrolled 10 healthy men. The Washington University RCT showing NMN 250 mg/day improved muscle insulin sensitivity enrolled 25 postmenopausal women specifically, making it the strongest women-specific human RCT to date. Its finding: NMN improved skeletal muscle insulin signaling (Akt and mTOR phosphorylation) compared to placebo over 10 weeks. That is encouraging, but 25 patients is a small sample.

A 2023 Cochrane-registered review protocol for NAD precursor supplementation in aging adults was registered but not yet completed as of this article's review date. Until that review publishes, clinicians should treat all NAD precursor recommendations as off-label, evidence-informed, and requiring explicit informed consent about the degree of uncertainty.

Be direct with your patients: the mechanism is biologically sound, the early human data are promising, and the safety profile at standard oral doses appears benign in short-term trials, but no large randomized trial in women across any life stage has been completed.

Quick-Reference Cheatsheet: Copy-Paste for Your EHR

DIAGNOSIS (ICD-10):
- PCOS: E28.2
- Post-menopause fatigue/cognitive: N95.1 or N95.8
- T2D/metabolic: E11.65
- Dyslipidemia (niacin): E78.5 or E78.00
- Chronic fatigue: R53.82
- Preventive/wellness: Z71.89 (counseling, other)

PROCEDURE (CPT):
- IV NAD infusion, hour 1: 96365
- IV NAD infusion, each additional hour: 96366
- Telehealth E/M: 99421 / 99422 / 99423
- Office E/M: 99213 / 99214 / 99215
- Preventive counseling (individual): 99401-99404
- Unlisted infusion (if payer requires): 96379

MODIFIERS:
- Modifier 25: E/M same day as procedure
- Modifier 95: Synchronous telehealth
- Modifier GT: Telehealth (Medicare)

CONTRACEPTION COUNSELING ADD-ON:
- Z30.09 when prescribing pharmacologic niacin
  to premenopausal patients

PREGNANCY: AVOID NMN, NR, high-dose niacin
LACTATION: Avoid high-dose; standard prenatal nicotinamide acceptable